4th Quarter - Report

GILEAD SCIENCES, INC. for GILEAD SCIENCES INC

Firm
Client
Income
—
Expenses
$320,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

HIV/AIDS Testing and Treatment; HIV/AIDS technology transfer and patent rights; HIV/AIDS Funding; Patient Protection and Affordable Care Act implementation

LobbyistCovered position, as disclosed
JOSEPH GROGAN —

Contacted: HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Commerce, Dept of (DOC); SENATE

Health Issues HCR

HIV Prevention; HIV Treatment and Testing; Intellectual Property Rights; Domestic HIV Policy Issues; Hepatitis B Funding for Screening and Linkage to Care Programs; Budget Control Act of 2011(P.L. 112-25); Ryan White Care Act Reauthorization; Hepatitis C Issues; HIV/AIDS testing and treatment; HIV/AIDS technology transfer and patent rights; HIV/AIDS Funding; Patient Protection and Affordable Care Act implementation; Federal Employes Health Benefits Program coverage; Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152)

LobbyistCovered position, as disclosed
JOSEPH GROGAN —

Contacted: Commerce, Dept of (DOC); SENATE; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

Medicare/Medicaid MMM

HIV/AIDS Testing and treatment; HIV/AIDS technology transfer and patent rights; HIV/AIDS funding; Patient Protection and Affordable Care Act Implementation; Hepatitis funding for screening and linkage to care programs

LobbyistCovered position, as disclosed
JOSEPH GROGAN —

Contacted: U.S. Trade Representative (USTR); SENATE; HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.